Trial Profile
ONO-1162 Phase II Study A placebo-controlled multicenter double-blind randomized parallel-group study in patients with chronic heart failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 27 Feb 2021 Results of meta-analysis of 6 studies, published in the Clinical Cardiology.
- 28 Jan 2016 New trial record
- 14 Jan 2016 Primary endpoint of reduction in resting HR from baseline at the 6-week treatment has been met according to results published in the Circulation Journal.